Organisation paid for research Program year 2025 Source: CMS Open Payments

NS Imaging Related Services Inc

Neither a doctor nor a teaching hospital

Research payments

$2,382,948

655 payments

Through program year 2025, NS Imaging Related Services Inc is reported as receiving $2,382,948 in research payments, across 655 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $164,650 64
2024 Research $126,235 60
2023 Research $245,118 83
2022 Research $205,931 74
2021 Research $494,811 149
2020 Research $682,315 160
2019 Research $463,887 65

Breakdown

Who paid Research payments · program years 2019–2025
  1. Acerta Pharma LLC $642,616 16 payments
  2. AstraZeneca UK Limited $437,533 29 payments
  3. AbbVie, Inc. $323,630 296 payments
  4. Pharmacyclics LLC, An AbbVie Company $224,830 58 payments
  5. Hoffmann-La Roche Limited $220,347 27 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $108,510 30 payments
  7. GlaxoSmithKline, LLC. $73,900 25 payments
  8. BioNTech SE $58,506 26 payments
  9. Roche Products Limited $43,380 12 payments
  10. F. Hoffmann-La Roche AG $40,900 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $476,975 15 payments
  2. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $250,500 3 payments
  3. Phase III Ipatasertib Plus Abirateron in McRpc 1St Line $153,710 10 payments
  4. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $123,128 4 payments
  5. M13-694 $93,960 7 payments
  6. A Phase 3 Randomized Open-Label Study of Brigatinib (Alunbrig?) Versus Alectinib (Alecensa?) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori?) $83,320 19 payments
  7. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-042, An An $72,050 21 payments
  8. Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma $61,450 7 payments
  9. A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects with Relapsed or Refractory Mantle Cell Lymphoma or other B-cell Malignancies $53,025 4 payments
  10. Ipatasertib in Combination With Paclitaxel in TNBC and HR Breast Cancer $51,390 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record